Zaltrap (aflibercept) is a type of targeted treatment known as a fusion protein. This treatment is designed to target multiple growth factors involved in cancer and angiogenesis, specifically proteins called VEGF-A, VEGF-B and a related protein called placental growth factor (PlGF).
Zaltrap is approved for use as treatment in second-line therapy in combination with chemotherapy (FOLFIRI) for metastatic bowel cancer.
Is Zaltrap available on the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Zaltrap had previously been approved by the Therapeutic Goods Administration (TGA) for use in Australia, however, as of January 2020 Zaltrap is no longer listed on the Australian Register of Therapeutic Goods (ARTG).
The ARTG is the register for all therapeutic goods that can be lawfully supplied in Australia. Sometimes a special provision is made to make available some medicines that are not listed in response to the needs of patients. To find out more visit the access to therapeutic goods on the ARTG website.
Download the Consumer Medicine Information (CMI) for Zaltrap.
